Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease
Open Access
- 9 February 2014
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 38 (3) , 380-387
Abstract
Factor XIII (FXIII) is necessary for cross linking of fibrin strands and generation of stable fibrin clot. FXIII Val34Leu is a common genetic single nucleotide polymorphism that has been associated with accelerated fibrin stabilization and reduced rate of fibrinolysis. The contribution of Val34Leu to long term risk of recurrent myocardial infarction (MI) in patients with coronary stenting has not been conclusively established. The objective of the study was to examine the effects of Val34Leu on fibrin generation, platelet aggregation, and long term clinical outcomes in patients with coronary artery disease treated with dual antiplatelet therapy. Patients with angiographically documented coronary artery disease who were treated with aspirin and clopidogrel were enrolled (n = 211). Light transmittance aggregometry and plasma fibrin clot formation using thrombelastography (TEG) were determined. Genotyping of Val34Leu was performed using Taqman assay. Clinical events during follow up were recorded. Homozygous carriers of 34Leu variant had significantly shorter fibrin clot formation time as compared to wild type individuals (TEG K: 1.27 ± 0.3 vs. 1.68 ± 1.1 min, p = 0.011). The Val34Leu variant was associated with gene dose dependent increased risk of MI (log rank, p = 0.002) or occurrence of composite of MI and CV death (log rank, p = 0.005) with highest event rates observed in homozygous carriers of 34Leu. In summary, FXIII Val34Leu polymorphism was associated with increased rate of fibrin stabilization in homozygous carriers of the variant and may increase risk of recurrent MI and death in patients with angiographically established coronary artery disease treated with dual antiplatelet therapy.Keywords
This publication has 31 references indexed in Scilit:
- Large-scale association analysis identifies new risk loci for coronary artery diseaseNature Genetics, 2012
- FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype – phenotype case control studyThrombosis and Haemostasis, 2011
- Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic RIsk Progression (TRIP) StudyPlatelets, 2010
- C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisThe Lancet, 2010
- Inflammation in AtherosclerosisJACC, 2009
- Polyphosphate as a general procoagulant agentJournal of Thrombosis and Haemostasis, 2008
- Variation in 24 hemostatic genes and associations with non‐fatal myocardial infarction and ischemic strokeJournal of Thrombosis and Haemostasis, 2008
- Inflammatory changes during the ‘common cold’ are associated with platelet activation and increased reactivity of platelets to agonistsBlood Coagulation & Fibrinolysis, 2007
- Factor XIII Val34Leu variant protects against coronary artery diseaseThrombosis and Haemostasis, 2007
- A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarctionJACC, 2004